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Advanced glycation end products (AGE), nonenzymatically glycated protein derivatives, have been implicated in
the development and progression of diabetic angiopathies, including skin dermopathy. Nevertheless, the
involvement of AGE in the development and progression of melanoma has not been fully elucidated. In this
study we investigated the expression levels of their receptor for AGE (RAGE) in human melanoma and
subsequently studied the effects of AGE on melanoma growth and migration. First, RAGE was detected in the
cytoplasm of human melanoma cells (G361 and A375). Among the different types of AGE, glyceraldehyde- and
glycolaldehyde-derived AGE signiﬁcantly stimulated the growth and migration of human melanoma cells.
Furthermore, tumor formation of melanoma cell xenografts in athymic mice was prevented by treatment with
anti-RAGE neutralizing antibodies. In tumor-bearing mice, survival rates were prolonged, and spontaneous
pulmonary metastases were inhibited by treatment using anti-RAGE neutralizing antibodies. In addition, all AGE
were present in beds of human melanoma tumor, whereas they were barely detected in normal skin. These results
suggest that AGE might be involved in the growth and invasion of melanoma through interactions with RAGE and
represent promising candidates for assessing the future therapeutic potential of this therapy in treating patients
with melanoma.
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The main cause of treatment failure and death for cancer
patients is metastasis—the formation of secondary tumors
in organs a long way from the original cancer. Among
cancers, melanoma is the most highly invasive and
metastatic tumor with an incidence and mortality that have
been rapidly increasing above those of any other cancers in
recent year (Morton et al, 1993). Adjuvant therapy of proven
efficacy is not currently available for these patients; there-
fore, the search for new targets for therapeutic reagents is
required to prevent both proliferation and metastasis.
Nevertheless, the molecular and genetic events that
contribute to the formation and progression of cutaneous
melanoma are poorly understood. It has been reported that
oxidative stress contributes to the pathogenesis of mela-
noma. Indeed, ultraviolet irradiation, one of the highest risk
factors for melanoma (McKie, 1998; Noonan, 2001), causes
oxidative DNA damage that is additionally potentially
mutagenic (Setlow et al, 1993).
Advanced glycation end products (AGE), nonenzymati-
cally glycated protein derivatives, were originally known to
accumulate in various tissues and have been implicated in
the development of diabetic vascular complications, for
example, retinopathy and nephropathy (Yang et al, 1994;
Stitt et al, 1997). Recent studies demonstrated that AGE
synthesis is accelerated by intra- and extracellular oxide
stress (Mullarkey et al, 1990). The receptor for advanced
glycation end products (RAGE), a multiligand member of the
immunoglobulin superfamily of cell surface molecules,
interacts with distinct molecules implicated in homeostasis,
development, and inflammation (Schmidt et al, 2001).
Binding RAGE by a ligand triggers activation of key cell-
signaling pathways, thereby reprogramming cellular proper-
ties. Recently Taguchi and colleagues (2000) have identified
RAGE in a molecular checkpoint that regulates not only the
invasiveness but also the growth and movement of glioma
cells. Nevertheless, the role of RAGE is still unclear in
melanoma proliferation and metastasis. One of the hypoth-
eses for the pathogenesis of melanoma growth and
migration suggests that AGE formed at an accelerated rate
under oxidative stress conditions might be involved in the
growth and invasion of melanoma through the interactions
with RAGE. In addition, we have previously elucidated the
pathways of AGE formation and characterized distinct AGE
classes (AGE1–5) and their different cell-mediated re-
sponses (Takeuchi et al, 1999, 2000a, b).
The aim of this study was to investigate whether distinct
AGE–RAGE interactions are a potential enhancer for growth
and/or cell migration in human melanoma cell.
Abbreviations: AGE, advanced glycation end product; CML, N-
(carboxymethyl)lysine; PBS, phosphate-buffered saline; PBS-T,
PBS-Tween; RAGE, receptor for advanced glycation end product.
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Results
RAGE expressed in human melanoma cells To investi-
gate whether RAGE proteins are detected in human
melanoma, melanoma cell lines (G361 and A375) and
normal melanocyte were immunohistochemically examined
using antibodies against RAGE. The results showed the
presence of RAGE protein in the membrane and cytoplasm
of these melanoma cells (Fig 1A), which is similarly staining
pattern with astrocytes (Sasaki et al, 2001). Melanocyte
expressed RAGE weakly compared melanoma cell. This
was confirmed by western blotting experiments in which
RAGE (35 kDa) was detected in melanoma cell extractions,
whereas normal melanocyte extraction contained lower
level of RAGE (Fig 1B). To further confirm these RAGE
expression results, quantitative analyses of RAGE mRNA
expression were undertaken using RT-PCR. The results
showed that RAGE mRNA (262 bp) was detected in two
melanoma cell lines (Fig 1C). Nevertheless, it was barely
detected in normal melanocytes. These data give a
consistent representation of RAGE expression observed in
the melanoma cell lines.
AGE2- and AGE3-induced cell proliferation of melanoma
cells in vitro The next experiment determined which AGE
induce melanoma cell growth in vitro. The immunochemi-
cally distinct AGE (AGE1, glucose-derived AGE; AGE2,
glyceraldehyde-derived AGE; AGE3, glycolaldehyde-
derived AGE; AGE4, methylglyoxal-derived AGE; AGE5,
glyoxal-derived AGE) (Takeuchi et al, 1999, 2000a, b) were
used. Various concentrations (0–1 mg/mL) of AGE were
added to the culture medium of G361 cells. Cell growth was
assessed using a modified MTS assay after a 48-h
incubation with the added compounds. Significant growth
stimulation with the addition of AGE2 and AGE3 was
observed (po0.01), whereas other AGE failed to enhance
cell proliferation (Fig 2A).
AGE2- and AGE3-induced migration and invasion in
melanoma cells in vitro Previous report indicated that
RAGE mediates migration of glioma cells (Taguchi et al,
2000); therefore, we then assessed these properties in
melanoma cells in vitro. First, we observed the morphologic
changes by caused the addition of AGE, involved in their
ability to extend processes necessary to migrate into the
surrounding matrix. The spreading cells were counted as
spindle cells if they showed a length-to-width ratio of more
than 3 (Fig 2B–D). The population of spindle cells was 24%
when G361 cells were cultured with no addition on
collagen-I-coated matrix. Only AGE2 and AGE3 increased
spindle cells population to 81% and 77, respectively
Figure 1
RAGE is expressed in human melanoma cell. (A) A375 and G361
melanoma cells cultured on slides were analyzed for RAGE using
confocal fluorescence microscopy. Control panels indicate the staining
with control IgG. Bars, 10 mm. (B) RAGE (35 kDa) and a-tubulin (50 kDa)
were analyzed by western blot of melanoma cells (A375, G361) and
melanocyte lysates. (C) RT-PCR was performed with RNA isolated from
melanoma cells (A375, G361) and melanocytes and degenerate primers
based on the RAGE and glyceraldehyde-3-phosphate dehydrogenase
amino acid sequences.
Figure2
AGE2- and AGE3-induced melanoma cell proliferation, migration,
and invasion in vitro. The medium of G361 melanoma cells was added
each AGE or CML (100 mg/mL or 1 mg/mL) for 48 h. (A) Proliferation
was assessed by WST-1 assay. po0.01 compared with medium
alone. (B) G361 cells were treated with AGE (1 mg/mL) and cultured on
plastic dishes coated with purified collagen I. After 18 h of incubation,
cells were photographed under phase contrast microscopy. (C) AGE2;
(D) no addition. Bars, 50 mm. The spreading cells are counted as
spindle cells if they had a length/width ratio greater than three.
po0.005 compared with medium alone. In migration and invasion
assay, G361 cells were layered on top of the membrane of Transwell
devices (E) or Matrigel-coated membrane (F). Cells were allowed to
migrate through the membrane for 16 h (migration assay) or 48 h
(invasion assay). Transmigrated cells were counted by crystal violet
staining. po0.005 compared with medium alone.
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(po0.005). To explore whether AGE enhance melanoma cell
migration and invasion, G361 cells were examined in
migration and invasion assays. The migration of G361 cells
was significantly enhanced by 138 and 108% by AGE2 and
AGE3, respectively (po0.005) (Fig 2E). Similarly, during
invasion assays, numbers of invading cells, which were able
to degradate Matrigel, also increased with the addition of
AGE2 and AGE3 (po0.005) (Fig 2F).
Anti-RAGE antibody inhibited melanoma cell prolifera-
tion induced by AGE2 and AGE3 It was investigated
whether anti-RAGE antibodies could inhibit AGE-induced
melanoma cell proliferation. This antibody was shown to
neutralize RAGE engagement; namely, it completely inhib-
ited G361 cell proliferation stimulated by either AGE2 or
AGE3 (Fig 3).
RAGE blockade suppressed growth of implanted mela-
noma in immunocompetent mouse Next we analyzed the
effects of anti-RAGE antibodies on the growth of melanoma
tumors using G361 melanoma xenografts in vivo. Initially,
mice were subcutaneously injected with G361 cells into
their upper flanks. After 10 d mice were treated intraper-
itoneally with 0.5 mg of either anti-RAGE antibody or control
IgG, once every 5 d. The mouse tumors treated with the
control antibody continued their aggressive growth to reach
the size of 400 mm3 by day 30 (Fig 4A). In contrast,
treatment with anti-RAGE antibody resulted in a significant
twofold reduction in tumor size compared with control IgG-
treated mice (n¼5/group, po0.01). To determine whether
RAGE tumor growth inhibition was associated with inhibi-
tion of tumor blood vessel formation, tumor fragments were
processed for histologic examination. Because the number
of capillaries was not different between tumor-treated anti-
RAGE antibodies and control IgG (Fig 4B,C), this tumor
growth suppression was not induced by inhibition of
angiogenesis.
RAGE blockade prolonged survival of tumor-bearing
mice and inhibited spontaneous lung metastasis G361
cells (1  106) were injected intraperitoneally into nude mice
to evaluate the effect of anti-RAGE antibody on the mortality
rate. Mice received intraperitoneal injections of 0.3 mL of
either control IgG (0.5 mg) or anti-RAGE antibody (0.5 mg)
10 d later and once every 5 d. The survival time of tumor-
bearing mice injected with anti-RAGE antibody was
significantly longer than tumor-bearing mice injected with
control IgG (n¼ 5/group, po0.05) (Fig 5A).
Next, we examined whether anti-RAGE antibodies
influenced metastasis in vivo. When the tumor volume size
established by the initial G361 injection into the upper flank
of nude mice reached 500 mm3, primary tumors were
excised. Mice were then maintained for an additional 3 wk
to allow further growth of lung metastases. Mice received
intraperitoneal injections of 0.3 mL of control IgG (0.5 mg) or
anti-RAGE antibody (0.5 mg) once every 3 d after tumors
were removed. The number of macroscopic surface lung
colonies per mouse was used as a parameter for judging
Figure 3
Anti-RAGE antibody inhibited the melanoma cell proliferation
induced by AGE2 and AGE3. The medium of G361 was added with
each AGE2 and AGE3 (1 mg/mL), anti-RAGE antibody (10 mg/mL), of
control IgG (10 mg/mL) as indicated for 48 h at 371C. The proliferations
were assessed by WST-1 assay. po0.005.
Figure4
RAGE blockade suppressed growth of implanted G361 melanoma,
not by inhibition of angiogenesis. (A) G361 melanoma cells (5  106)
were injected subcutaneously into the upper flank of Balb/c-nu/nu mice
(n¼5/group). Mice received intraperitoneal injections of PBS, control
IgG (0.5 mg), or anti-RAGE antibodies (0.5 mg) after 10 d; they were
injected every 5 days. Tumor weights (average  SD) were measured.
po0.01. For immunohistochemical analysis of microvessels in the
tumor tissues, sections were stained with anti-CD34 (FITC, green)
antibody. Nuclei were stained with propidium iodide (red). Microvessels
in the anti-RAGE antibody-treated melanoma tissues (B) and control
IgG-treated melanoma tissue (C). Bars, 50 mm.
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the lung colonization efficiency. The metastatic efficiency
was markedly reduced in mice treated with anti-RAGE
antibody (n¼ 5/group, po0.05) (Fig 5B).
AGE and RAGE expressed in human melanoma tissue
To investigate whether AGE and RAGE proteins are
detected in human melanoma in vivo, human melanoma
specimens were immunohistochemically examined for
antibodies against various types of immunochemically
distinct AGE (AGE1-5), CML, and RAGE. The results
showed that AGE2 was strongly present within cytoplasm
of melanoma cells and in the extracellular matrix (Fig 6A). All
of other AGE and CML were similarly stained (data not
shown). In contrast, RAGE was detected only in cytoplasm
of melanoma cells. In normal skin, AGE and CML were
hardly detected, and also RAGE was hardly stained in
melanocytes (data not shown).
Discussion
Here we demonstrate that RAGE was expressed in human
melanoma cells. Furthermore, glyceraldehyde-derived AGE
(AGE2) and glycolaldehyde-derived AGE (AGE3) enhanced
proliferation, migration, and invasion of this melanoma cell
line in vitro. Finally, the treatment by intraperitoneal injection
of the neutralizing anti-RAGE antibody reduced local tumor
formation, prolonged survival rate, and inhibited lung
metastases in nude mice.
It has been reported that RAGE is expressed by a range
of cell types, including endothelial cell, astrocytes, and
some malignant cells such as malignant glioma and
squamous cell carcinoma, contributing to homeostasis,
development, inflammation, and carcinogenesis (Mullarkey
et al, 1990; Yamagishi et al, 1997; Yamamoto et al, 1995;
Sasaki et al, 1998). We and other groups have reported that
AGE were present in various tissues including endothelial
cells of blood vessel, mesenchymal cells, and extracellular
matrix (Ling et al, 1998; Mizutari et al, 1997). Accumulation
of AGE initiated various important processes including
angiogenesis in diabetic microangiopathies (Yamagishi et
al, 1997). AGE formation in the extracellular matrix of skin is
accelerated by ultraviolet-induced oxidation (Mizutari et al,
1997), and AGE generate active oxygen species in the skin
during ultraviolet irradiation (Masaki et al, 1997), suggesting
the presence of vicious cycle of AGE formation. Further-
more, AGE can activate RAGE expression causing en-
hanced AGE–RAGE interaction (Tanaka et al, 2000). It is
thus hypothesized that activated cells that include not only
tumor cells but also stromal cells located in peritumor site
synthesize AGE. Taken together, we hypothesize that
convenient for melanoma cells proliferate and invade with
abundant accumulation of extracellular AGE in skin.
We have highlighted the pathways of AGE formation and
characterized distinct AGE classes (AGE1–5) with different
cell-mediated responses (Takeuchi et al, 1999, 2000a, b). In
this study, AGE2 and AGE3 but not other AGE, can
upregulate melanoma cell growth, migration, and invasion
in vitro. Recently, we also reported strong RAGE binding by
Figure 5
RAGE blockade prolonged survival of tumor-bearing mouse and
inhibited spontaneous lung metastasis. (A) A single-cell suspension
of 1  106 G361 melanoma cells was injected into the peritoneal cavity
of 6-wk-old female athymic nude mice (n¼5/group). Mice received
intraperitoneal injections of 0.3 mL of control IgG (0.5 mg) or anti-RAGE
antibodies (0.5 mg) after 10 d and once per 5 days. Mice were then
observed for survival, which was recorded as the percentage of
surviving animals over time (in days) after tumor injection. po0.01. (B)
1  106 G361 cells were injected into the upper flank of nude mice
(n¼ 5/group). When the mean tumor volume reached 500 mm3, primary
tumors were removed. Mice were then maintained for an additional 3
wk to allow further growth of lung metastases. Mice received
intraperitoneal injections of control IgG (0.5 mg) or anti-RAGE
antibodies (0.5 mg) once every 3 d after tumors were removed. The
mice were necropsied, and the lungs were removed. Visible lung
metastases were counted with the aid of a dissecting microscope.
po0.01.
Figure6
AGE and RAGE are expressed in human melanoma. Immunohisto-
chemical preparations stained with anti-AGE2 (A), anti-RAGE (B), and
control IgG (C) using the avidin-biotin immunoperoxidase method. The
data of other AGE and CML were not shown. (A, arrow) Intracellular and
(arrowhead) extracellular AGE2 localization. Bars, 10 mm.
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AGE2 and AGE3, but not other AGE (Yonekura et al, 2003).
Taken together, AGE2– and AGE3–RAGE interactions have
an important role in the progression of melanoma. Although
previous papers reported that CML–RAGE interaction
mediates cell signaling (Kislinger et al, 1999), our data
showed CML influence little effects on melanoma prolifera-
tion, migration, and invasion. We speculate that this
disparity is dependent on cell types or transformation
(malignant or normal).
We also assessed the therapeutic efficacy of AGE–RAGE
interactions in a xenograft model. In our experiments,
blocking RAGE by the systemic administration of neutraliz-
ing RAGE antibody significantly inhibited the growth of
G361 xenograft tumors and spontaneous lung metastasis.
Furthermore, the blockade of RAGE prolonged the survival
of G361 tumor-bearing mice. Previously we reported that
this interaction could play a significant role in the progres-
sion of pancreatic cancer through the induction of autocrine
platelet-derived growth factor-B (Yamamoto et al, 1995).
Furthermore, Taguchi and associates (2000) showed that
this interaction regulates not only the growth but also the
movement and invasiveness of glioma tumor cells (Mullar-
key et al, 1990). In addition, the presence of AGE was
confirmed in human melanoma beds, whereas those were
barely detected in normal skin, indicating that the interac-
tion of upregulated RAGE in melanoma cells and AGE that
are present in tumor beds promotes melanoma progression.
We concluded that these interactions regulate various
malignant tumors, which have a particularly high invasive
and metastatic potential.
In conclusion, our findings have identified a pivotal role
for AGE–RAGE interactions in human melanoma growth
and metastasis. We suggested that blockage of these
interactions, including using the anti-RAGE antibody are
represent a good candidates for treatment of patients with
melanoma.
Materials and Methods
Human melanoma specimens Two consecutive cases of mela-
noma tissue biopsies taken for routine diagnosis with patient
consent and ethical permission were retrieved from the Depart-
ment of Dermatology, Hokkaido University Graduate School of
Medicine.
Mice and cell lines Balb/c-nu/nu mice were purchased from
Japan Clea (Tokyo, Japan) and maintained under specific patho-
gen-free conditions. All animal procedures were conducted
according to guidelines from the Hokkaido University Institutional
Animal Care and Use Committee under an approved protocol. The
two human melanoma cell lines, G361 and A375 (American Type
Culture Collection, Manassas, VA) were maintained in RPMI 1640
supplemented with 10% fetal calf serum, 100 units per mL
penicillin/streptomycin. Normal human neonatal melanocytes were
purchased from Kurabo (Osaka, Japan) and were cultured
according to the manufacturer’s instructions.
Preparation of AGE proteins and N-(carboxymethyl)lysine–
bovine serum albumin AGE–bovine serum albumin and AGE–
rabbit serum albumin were prepared as described previously
(AGE1, glucose-derived AGE; AGE2, glyceraldehyde-derived AGE;
AGE3, glycolaldehyde-derived AGE; AGE4, methylglyoxal-derived
AGE; AGE5, glyoxal-derived AGE) (Takeuchi et al, 1999, 2000a, b).
Carboxymethyllysine (CML)–bovine serum albumin was prepared
as described elsewhere (Ikeda et al, 1996). Protein concentrations
were determined with the DC protein assay reagent (Bio-Rad
Laboratories, Richmond, CA) using bovine serum albumin as a
standard.
Preparation of antibodies A polyclonal antibody against RAGE
was raised in rabbits (Sasaki et al, 2001). The peptides were
synthesized according to the amino acid sequences of RAGE,
residues 167 to 180 in extracellular domain. Synthesized peptide
was coupled to keyhole limpet hemocyanin and mixed with an
equal volume of Freund’s complete adjuvant. The conjugated
peptide were injected into rabbits three times at 2-wk intervals.
Serum was obtained 2 wk after last injection, and antibody titer
was assessed by ELISA. This anti-RAGE antibody certainly
recognizes full-length RAGE (Sasaki et al, 2001). For in vivo
experiments, the IgG fraction of antiserum was purified by
Sepharose A. Antibodies specific for all AGE (AGE1–5 and CML)
were prepared as previously described (Takeuchi et al, 1999,
2000a, b).
Immunoﬂuorescence microscopy Immunofluorescence staining
was performed on melanoma cells grown on glass coverslips. The
glass coverslips were incubated with anti-RAGE antibody (1:100
dilution) overnight at 41C in Tris-buffered saline containing 1%
bovine serum albumin. The primary antibodies were detected
using fluorescein isothiocyanate-labeled goat anti-rabbit IgG
(Vector Laboratories, Burlingame, CA). The glass coverslips were
examined using a confocal laser microscope (laser scanning
confocal imaging system Model MRC 1024, Bio-Rad) equipped
with an inverted fluorescence microscope (Zeiss, Germany).
Western blot G361, A375, and normal melanocytes were grown
to confluence in 100-mm dishes, washed with phosphate-buffered
saline (PBS), and lyzed as previously described (Shimizu et al,
1999). Samples containing 50 mg of protein were loaded onto 10%
acrylamide gels. Proteins were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and electrophoretically
transferred to nitrocellulose filters. After transfer, the filters were
blocked by incubation with 5% nonfat dry milk in PBS-Tween
(PBS-T) buffer overnight at room temperature. The filters were then
incubated for 1 h with PBS-T containing 0.1% nonfat dry milk and
the anti-RAGE antibody at 1:2500 dilution or a-tubulin antibody
(Santa Cruz Biotechnology, Santa Cruz, CA) at 1:1000. Next, the
filters were washed three times in PBS-Tand incubated with PBS-T
containing 0.1% nonfat dry milk and horseradish peroxidase-linked
anti-rabbit Ig [F(ab0)2] (Amersham-Life Science, Buckinghamshire,
UK) diluted 1:5000 for 1 h at room temperature. Filters were
washed three more times in PBS-T, and immunoreactivity was
detected using an enhanced chemiluminescence western blot
detection system (Amersham), followed by exposure to ECL
HYPER film (Amersham).
Reverse transcription-polymerase chain reaction In brief, PCR
was carried out as previously described (Tanji et al, 2000). The
sense primer for RAGE was from bp 1801 to bp 1820 (50-
GCCCTCCAGTACTACTCTCG-30), and the antisense primer was
from bp 2043 to bp 2062 (50-TGTGTGGCCACCCATTCCAG-30).
The sense and antisense primers for glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) were from bp 204 to bp 226 (50-
CAATGGAAATCCCATCACCATCT-30) and from bp 908 to bp 930
(50-AATGAGCTTGACAAAGTGGTCGT-30), respectively. The entire
RT reaction product was used for PCR amplification. Forty cycles
of amplification were performed using a thermal programmer
(Perkin Elmer, Wellesley, MA), as follows: denaturation at 941C for
15 s and annealing and extension at 601C for 30 s. The PCR
products were then electrophoresed on a 1.5% agarose gel
stained with ethidium bromide.
Proliferation assay The cell proliferations were assessed by
using a modified MTT assay, the WST-1 assay, which is a
colorimetric assay based on the cleavage of the tetrazolium salt
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WST-1 to a formazan dye by the mitochondrial dehydrogenase of
viable cells. G361cells (5  103 cells per well) were preincubated
for 24 h with serum-free medium at 371C. The medium was
replaced with medium containing each AGE, CML (0–1 mg/mL) or
anti-RAGE antibody (10 mg/mL) and control IgG (10 mg/mL) for 48 h
at 371C. The ready-to-use WST-1 reagent (Dojin, Kumamoto,
Japan) was added to the cells during the last 4 h and incubated at
371C. Viable cells were then determined using a microplate reader
at 450 nm with a 630-nm reference wavelength.
Transmigration and invasion assays To examine the properties
of the tumors grown by AGE, G361 cells were added to plastic
dishes (Nunc, Naperville, IL) coated with purified collagen I. After
18 h, cells were photographed under phase contrast microscopy.
The spreading cells were counted as spindle cells if they had a
length/width ratio greater than 3. In a transmigration assay, the
upper side of a modified Boyden chamber polycarbonate
membrane (Transwell 24, 8-mm pore, Costar, Cambridge, MA)
(Albini et al, 1987) either was left uncoated (transmigration) or was
coated (invasion) with Matrigel (1 mg/mL) (Matrigel-GFR, Falcon-
Becton Dickinson, Bedford, MA) for 2 h at room temperature
(Kleinman et al, 1986). Cells were then seeded in the upper
chambers in their respective culture medium without fetal bovine
serum but containing AGE, and incubated for either 16 h
(transmigration) or 48 h (invasion) at 371C. The chambers were
fixed and stained with crystal violet. The cells on the lower surface
of the filter were counted (two fields/well) using a microscope with
a  10 objective. Each condition was assayed in triplicate, and
each experiment was repeated at least three times.
Tumor growth in vivo Experiments to determine the effect of
anti-RAGE antibodies on G361 tumor growth were performed in
Balb/c-nu/nu mice. Cultured G361 cells were washed and
resuspended in PBS; subsequently 5  106 cells (suspended in
0.1 mL of PBS) were injected subcutaneously into the upper flank
of 6-wk-old female athymic nude mice (n¼ 5/group). Mice received
intraperitoneal injections of 0.3 mL of control IgG (0.5 mg) or anti-
RAGE antibodies (0.5 mg) 10 d later and from then on once every 5
days. Tumor size was estimated on day 30 using orthogonal linear
measurements made with Vernier calipers according to the formula
volume (mm3)¼ [(width, mm)2  (length, mm)]/2. This experiment
was repeated twice with similar results. Blood vessels in the tumor
were visualized by CD34 staining, which was performed on
cryosections using the fluorescein isothiocyanate-conjugated rat
anti-mouse CD34 (PharMingen, San Diego, CA). Nuclei were
stained with propidium iodide.
Survival and in vivo metastasis assays A single-cell suspension
of 1  106 G361 cells was injected into the peritoneal cavity of 6-
wk-old female athymic nude mice (n¼ 5/group). Mice received
intraperitoneal injections of 0.3 mL of control IgG (0.5 mg) or anti-
RAGE antibodies (0.5 mg) 10 d later and from then every 5 d. Mice
were then observed for survival, which was recorded as the
percentage of surviving animals over time (in days) after tumor
injection. To measure the spontaneous metastasis, 1  106 cells
were injected into the upper flank of 6-wk-old athymic nude mice
(n¼ 5/group). When the mean tumor volume reached 500 mm3,
primary tumors were removed. Mice were then maintained for an
additional 3 wk to allow further growth and development of lung
metastases. Mice received intraperitoneal injections of 0.3 mL of
control IgG (0.5 mg) or anti-RAGE antibodies (0.5 mg) once every 3
d after tumors were removed. The mice were necropsied, and the
lungs were removed. Visible lung metastases were counted with
the aid of a dissecting microscope.
Immunohistochemical staining Serial paraffin sections were
immunostained according to the standard streptavidin-biotin
peroxidase technique using a Vectastain ABC elite kit (Vector
Laboratories). After incubation with 10% goat serum to eliminate
nonspecific binding, these sections were followed by incubation
overnight at 41C with the primary antibodies diluted 1:500 to
1:1000 in PBS. The sections were then sequentially incubated with
the biotinylated secondary antibody. Then the sections were
counterstained with hematoxylin.
Statistical analysis The data were statistically analyzed for
significance by Student’s t test, except for the in vivo survival
assays, which were analyzed using Wilcoxon analysis.
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